[{"orgOrder":0,"company":"Nanjing Yoko Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Clevidipine","moa":"phenylpyridine vasodilators (nifedipine type)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Nanjing Yoko Biomedical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanjing Yoko Biomedical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nanjing Yoko Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"CSPC Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Clevidipine","moa":"phenylpyridine vasodilators (nifedipine type)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"CSPC Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSPC Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CSPC Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Methodist Healthcare","sponsor":"The Medicines Company","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Clevidipine","moa":"phenylpyridine vasodilators (nifedipine type)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Methodist Healthcare","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Insert","sponsorNew":"Methodist Healthcare \/ The Medicines Company","highestDevelopmentStatusID":"11","companyTruncated":"Methodist Healthcare \/ The Medicines Company"},{"orgOrder":0,"company":"Columbia University","sponsor":"The Medicines Company","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Clevidipine","moa":"phenylpyridine vasodilators (nifedipine type)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Columbia University \/ The Medicines Company","highestDevelopmentStatusID":"11","companyTruncated":"Columbia University \/ The Medicines Company"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ITALY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Clevidipine","moa":"Voltage-gated L-type calcium channel","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chiesi Group \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chiesi Group \/ Undisclosed"},{"orgOrder":0,"company":"Duke University","sponsor":"The Medicines Company","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Clevidipine","moa":"Voltage-gated L-type calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Duke University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Duke University \/ The Medicines Company","highestDevelopmentStatusID":"1","companyTruncated":"Duke University \/ The Medicines Company"},{"orgOrder":0,"company":"North Texas Veterans Healthcare System","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Clevidipine","moa":"Voltage-gated L-type calcium channel","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"North Texas Veterans Healthcare System","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"North Texas Veterans Healthcare System \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"North Texas Veterans Healthcare System \/ Undisclosed"},{"orgOrder":0,"company":"The Medicines Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Clevidipine","moa":"Voltage-gated L-type calcium channel","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"The Medicines Company","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Medicines Company \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"The Medicines Company \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for DSSTox_CID_31450

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Aquaexpo
                          Not Confirmed
                          Aquaexpo
                          Not Confirmed

                          Details : Clevidipine Butyrate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypertensive Crisis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 24, 2023

                          Lead Product(s) : Clevidipine

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Nanjing Yoko Biomedical

                          Country arrow
                          Aquaexpo
                          Not Confirmed

                          Nanjing Yoko Biomedical

                          Country arrow
                          Aquaexpo
                          Not Confirmed

                          Details : Clevidipine Butyrate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypertensive Crisis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 17, 2020

                          Lead Product(s) : Clevidipine

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Aquaexpo
                          Not Confirmed
                          Aquaexpo
                          Not Confirmed

                          Details : Clevidipine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dyspnea.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 19, 2020

                          Lead Product(s) : Clevidipine

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Aquaexpo
                          Not Confirmed
                          Aquaexpo
                          Not Confirmed

                          Details : Clevidipine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 10, 2013

                          Lead Product(s) : Clevidipine

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Aquaexpo
                          Not Confirmed
                          Aquaexpo
                          Not Confirmed

                          Details : Clevidipine Butyrate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypertension.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 06, 2012

                          Lead Product(s) : Clevidipine

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase IV

                          Sponsor : The Medicines Company

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Duke University

                          Country arrow
                          Aquaexpo
                          Not Confirmed

                          Duke University

                          Country arrow
                          Aquaexpo
                          Not Confirmed

                          Details : Clevidipine is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Aortic Aneurysm.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 29, 2011

                          Lead Product(s) : Clevidipine

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : The Medicines Company

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          North Texas Veterans Healthcare System

                          Country arrow
                          Aquaexpo
                          Not Confirmed

                          North Texas Veterans Healthcare System

                          Country arrow
                          Aquaexpo
                          Not Confirmed

                          Details : Clevidipine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypertension, Pulmonary.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 12, 2010

                          Lead Product(s) : Clevidipine

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Methodist Healthcare

                          Country arrow
                          Aquaexpo
                          Not Confirmed

                          Methodist Healthcare

                          Country arrow
                          Aquaexpo
                          Not Confirmed

                          Details : Clevidipine Butyrate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypertension.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 05, 2010

                          Lead Product(s) : Clevidipine

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase IV

                          Sponsor : The Medicines Company

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank